_2020091018165303jzv.jpg "Decoding The World Of ETF")
BUSINESS
Amber Enterprises: A worthy buy despite expensive valuation
Tailwinds such as low penetration of ACs in India, high entry barriers, increasing inverter AC sales, and higher disposable incomes are expected to augur well for the company.
BUSINESS
100% FDI in single-brand retail: A much-needed booster shot?
The Union Cabinet, in a landmark move for Indian retail, announced some noteworthy changes in norms pertaining to single-brand foreign direct investments (FDI) in India, thereby making it considerably easier for global retailers to gain access to the highly dynamic and fast-growing Indian markets
BUSINESS
Future Retail may buy Hypercity from Shoppers Stop – a win-win for both buyer and seller
By acquiring Hypercity, Future Retail aims to leverage its retail capabilities by building economies of scale, reducing overall cost of operations, expanding the number of small/convenience outlets (especially in the metros), and pushing the sales of its margin-accretive private label consumer products.
BUSINESS
ICICI Lombard IPO – get insured for the long-term
Industry tailwinds, increased awareness towards insurance products, leadership status amongst private non-life insurers in India, a robust distribution channel, and healthy financials make ICICI Lombard's IPO a proposition worth considering.
BUSINESS
V-Mart Retail's volume push to fire up margins
The company is poised to grow from the boom in India’s retail space inspite of the high competitive intensity from large format stores and online portals.
BUSINESS
Himatsingka Seide: A consistent performer with a solid outlook
The company continues to leverage on its fundamental strengths optimally, as evident from the numbers in the quarter gone by.
BUSINESS
Textiles under GST: Relief on one hand, a whammy on the other
Though the effect of GST-induced disruptions can't be ignored in the near-term, the Indian textile industry is poised to grow from the long-term benefits that the new legislation offers.
BUSINESS
Is Eris Lifesciences the correct prescription for you?
With a predominant focus on the domestic formulations market, a robust portfolio of largely prescription-based drugs, and a tilt towards a promising chronic portfolio, the company seems fundamentally strong.
BUSINESS
Why this midcap company could be spinning its way to the top
Although Nitin Spinners doesn’t have a unique product line or process, what puts it on the map for investors is its performance potential for the forthcoming years.
BUSINESS
Bumpy ride for commercial vehicle companies far from over
Medium and heavy commercial vehicle companies would be staring at a difficult earnings season and the impact can linger on for a couple of more months.
BUSINESS
Do FIIs and DIIs really drive the markets? Here’s what correlations say
Investors should clearly select stocks on merit rather than blindly following flow patterns. Tracking smart money in the long term doesn’t necessarily generate smart returns.
BUSINESS
Key lesson from FY17 IPOs: Don’t fret if you miss the bus
The key takeaway from our analysis for the prospective investor is that if he has missed the IPO bus last year, it makes sense to ride it with good IPOs in FY18.
